Bruker Corporation (BRKR - Free Report) , a designer and manufacturer of proprietary life science and materials research systems and associated products, rallied 31.7% over the last three months, ahead of the S&P 500’s 5.2% gain and the Zacks categorized Instruments - Scientific sub-industry's 21.9%. The stock has a market cap of $4.63 billion.The company’s five-year historical growth rate is also favorable at 8.5% as compared to 2.8% of the S&P 500 index and 0.8% of the broader industry. Average volume of shares traded over the last one year was remarkable at approximately 752K.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick at present.
Let’s find out whether the recent positive trend is a sustainable one.
Headquartered in Billerica, MA, the company has a stellar four-quarter average earnings surprise of 21.1%.
The market is currently upbeat about Bruker’s several new and advanced, high-performance mass spectrometry solutions for Maldi Imaging, metabolomics, proteoform profiling and toxicology introduced at ASMS 2017. These include the advanced MALDI Imaging solutions integrating SCiLS mass-spec imaging software with the rapifleX high-throughput MALDI-TOF/TOF system, or MALDI-Magnetic Resonance Mass Spectrometry (MRMS) extreme resolution system for drug and metabolite tissue imaging. The company has also showcased timsTOF research system, Metabolomics research and Phenomics translational research solutions, Proteoform Profiling solution, and a routine forensic Toxicology platform.
Also, we are encouraged about the recent launch of S8 TIGER Series 2– the next-generation Wavelength Dispersive X-Ray Fluorescence (WDXRF) spectrometer. S8 TIGER Series 2 is the most versatile WDXRF tool available for advanced quantitative elemental analysis in industrial and academic materials research as well as in industrial quality control (QC) of materials.
While the markets expect Bruker’s financial results for the second quarter of 2017to be out on Aug 1, strong first-quarter 2017 revenue performance and the raised full-year 2017 revenue guidance which calls for an increase of 2–3.5% over the prior year have boosted investors’ confidence in the stock.
A few better-ranked medical stocks are Mesa Laboratories, Inc. (MLAB), INSYS Therapeutics, Inc. (INSY) and Align Technology, Inc. (ALGN). Notably, Mesa Laboratories and INSYS Therapeutics sport a Zacks Rank #1 (Strong Buy), while Align Technology carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Mesa Laboratories has a positive earnings surprise of 2.84% for the last four quarters. The stock has added roughly 8.8% over the last three months.
INSYS Therapeutics has a long-term expected earnings growth rate of 20%. The stock has gained around 16.5% over the last three months.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 32.7% over the last three months.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>